![]() |
|
|
Authored by
The Faculty Disclosure Policy of the Albert Einstein College of Medicine requires that faculty participating in a CME activity disclose to the audience any relationship with a pharmaceutical or equipment company that might pose a potential, apparent, or real conflict of interest with regard to their contribution to the activity. It is required by the ACCME that any mention of an unlabeled use of a commercial product or device or an investigational use not yet approved by the FDA be disclosed to participants. Gail de Imus, MD, has served as a consultant to Novartis Pharmaceuticals Corporation.
Vincent Falanga, MD, FACP, has received grant/research support from and served as a consultant
to Novartis Pharmaceuticals Coporation and Organogenesis, Inc. Evan Lipsitz, MD, disclosed
no conflicts of interest. |
|
![]() |
|
|
Authored by
Joseph P. Cavorsi, MD The Faculty Disclosure Policy of the Albert Einstein College of Medicine requires that faculty participating in a CME activity disclose to the audience any relationship with a pharmaceutical or equipment company that might pose a potential, apparent, or real conflict of interest with regard to their contribution to the activity. It is required by the ACCME that any mention of an unlabeled use of a commercial product or device or an investigational use not yet approved by the FDA be disclosed to participants. Joseph P. Cavorsi, MD, disclosed no conflicts of interest. Evan Lipsitz, MD, disclosed no conflicts of interest.
|
|